Celcuity Drug Patent Portfolio
Celcuity owns 1 orange book drug protected by 7 US patents Given below is the list of Celcuity's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12350276 | Methods For The Treatment Of Cancer Using 1-(4-{[4-(Dimethylamino)Piperidin-1-Yl]Carbonyl}Phenyl)-3-[4-(4,6-Dimorpholin-4-Yl-1,3,5-Triazin-2-Yl)Phenyl]Urea | 31 Aug, 2042 | Active |
| US12109308 | Aqueous Formulation Comprising 1-(4-{[4-(Dimethylamino)Piperidin-1-Yljcarbonyl}Phenyl)-3-[4-(4,6-Dimorpholin-4-Yl-1,3,5-Triazin-2-Yl)Phenyl]Urea | 02 Jan, 2041 | Active |
| US8039469 | Triazine Compounds As Pi3 Kinase And Mtor Inhibitors | 17 Dec, 2029 | Active |
| US8217036 | Triazine Compounds As Pi3 Kinase And Mtor Inhibitors | 22 May, 2029 | Active |
| US8575159 | Triazine Compounds As Pi3 Kinase And Mtor Inhibitors | 22 May, 2029 | Active |
| US8748421 | Triazine Compounds As P13 Kinase And Mtor Inhibitors | 22 May, 2029 | Active |
| US9174963 | Triazine Compounds As Pi3 Kinase And Mtor Inhibitors | 22 May, 2029 | Active |
Celcuity's Family Patents
Clinical Trials
Recent Clinical Trials by Celcuity:
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
| ||||
| Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2) | Celcuity Inc | NA |
RECRUITING
(May 1, 2026)
| PHASE3 |
| Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer | Celcuity Inc | NA |
RECRUITING
(Apr 1, 2026)
| PHASE1, PHASE2 |
Celcuity Drug List
Given below is the complete list of Celcuity's drugs and the patents protecting them.
1. Revtorpyk
Revtorpyk is protected by 7 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12350276 | Methods For The Treatment Of Cancer Using 1-(4-{[4-(Dimethylamino)Piperidin-1-Yl]Carbonyl}Phenyl)-3-[4-(4,6-Dimorpholin-4-Yl-1,3,5-Triazin-2-Yl)Phenyl]Urea |
31 Aug, 2042
(15 years from now)
| Active |
| US12109308 | Aqueous Formulation Comprising 1-(4-{[4-(Dimethylamino)Piperidin-1-Yljcarbonyl}Phenyl)-3-[4-(4,6-Dimorpholin-4-Yl-1,3,5-Triazin-2-Yl)Phenyl]Urea |
02 Jan, 2041
(14 years from now)
| Active |
| US8039469 | Triazine Compounds As Pi3 Kinase And Mtor Inhibitors |
17 Dec, 2029
(3 years from now)
| Active |
| US8217036 | Triazine Compounds As Pi3 Kinase And Mtor Inhibitors |
22 May, 2029
(2 years from now)
| Active |
| US8575159 | Triazine Compounds As Pi3 Kinase And Mtor Inhibitors |
22 May, 2029
(2 years from now)
| Active |
| US8748421 | Triazine Compounds As P13 Kinase And Mtor Inhibitors |
22 May, 2029
(2 years from now)
| Active |
| US9174963 | Triazine Compounds As Pi3 Kinase And Mtor Inhibitors |
22 May, 2029
(2 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Revtorpyk's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List